Plasma β-Amyloid in Mild Behavioural Impairment – Neuropsychiatric Symptoms on the Alzheimer's Continuum. (May 2022)

• Record Type: Journal Article
• Authors: Miao, Ruxin; Chen, Hung-Yu; Gill, Sascha; Naude, James; Smith, Eric E.; Ismail, Zahinoor
• Is Part Of: Journal of geriatric psychiatry and neurology. Volume 35:Number 3(2022)
• Page Start: 434
• Page End: 441
• Publication Date: 2022-05
• Subjects: Alzheimer's disease -- mild behavioural impairment -- beta-amyloid -- neuropsychiatric symptoms; Geriatric neurology -- Periodicals; Geriatric neuropsychiatry -- Periodicals; Geriatric psychiatry -- Periodicals; Nervous system -- Diseases -- Periodicals; 618.97689
• DOI: 10.1177/08919887211016068
• Languages: English
• ISSNs: 0891-9887

Abstract

Introduction: Simple markers are required to recognize older adults at higher risk for neurodegenerative disease. Mild behavioural impairment (MBI) and plasma β-amyloid (Aβ) have been independently implicated in the development of incident cognitive decline and dementia. Here we studied the associations between MBI and plasma Aβ42 /Aβ40 . Methods: Participants with normal cognition (n = 86) or mild cognitive impairment (n = 53) were selected from the Alzheimer's Disease Neuroimaging Initiative. MBI scores were derived from Neuropsychiatric Inventory items. Plasma Aβ42 /Aβ40 ratios were assayed using mass spectrometry. Linear regressions were fitted to assess the association between MBI total score as well as MBI domain scores with plasma Aβ42 /Aβ40 . Results: Lower plasma Aβ42 /Aβ40 was associated with higher MBI total score ( p = 0.04) and greater affective dysregulation ( p = 0.04), but not with impaired drive/motivation ( p = 0.095) or impulse dyscontrol ( p = 0.29) MBI domains. Conclusion: In persons with normal cognition or mild cognitive impairment, MBI was associated with low plasma Aβ42 /Aβ40 . Incorporating MBI into case detection may help capture preclinical and prodromal Alzheimer's disease.